Carregant...
A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy
Chimeric antigen receptor (CAR) T cells targeting CD19 have been successful treating patients with relapsed/refractory B cell acute lymphoblastic leukemia (ALL) and B cell lymphomas. However, relapse after CAR T cell therapy is still a challenge. In addition, preclinical and early clinical studies t...
Guardat en:
| Publicat a: | Front Oncol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7058784/ https://ncbi.nlm.nih.gov/pubmed/32185132 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00262 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|